Aethlon medical prepares for potentially transformative phase 1 cancer treatment studies

Phase 1 clinical trials of the hemopurifier® designed to include patients with solid tumors who have stable or progressive disease during anti-pd-1 monotherapy treatment, such as keytruda® of opdivo® interested clinical sites have initiated submissions for ethics committee review san diego , june 3, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-pd-1 monotherapy treatment, such as keytruda® or opdivo®. "we continue to make progress preparing for our planned, safety, feasibility and "dose finding" oncology trials in australia and india, and want to provide our shareholders and other constituents with an update, stated steven larosa, md, chief medical officer of aethlon medical.
AEMD Ratings Summary
AEMD Quant Ranking